January 25, 2017
Biogen Japan is gearing up for its new start as a multiple sclerosis (MS) powerhouse with the planned spin-off of its hemophilia business and the upcoming launch of Tecfidera (dimethyl fumarate), looking to eventually become a neurology specialty pharma that...read more